Nima Radkhah

Nima Radkhah

Auto-generated profile, based on publicly available information

Nima Radkhah

Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2023 in Advances in Nutrition
Verified
Journal Article
Open access
NRNima Radkhah
Nima Radkhah
MZMeysam Zarezadeh
Meysam Zarezadeh
PJParmida Jamilian
Parmida Jamilian
AOAlireza Ostadrahimi
Alireza Ostadrahimi
According to published meta-analyses, vitamin D exerts different beneficial effects in preventing and controlling risk factors associated with noncommunicable chronic diseases; however, the results are still conflicting. The purpose of this umbrella meta-analysis was to investigate the effect of vitamin D supplementation on low-density lipoprotein cholesterol, high-density lipoprotein (HDL) cholesterol, total cholesterol (TC), and triglyceride (TG) as components of the lipid profile. PubMed, Scopus, Web of Science, and Cochrane Database of Systematic Reviews were systematically searched for meta-analyses of randomized controlled trials. The umbrella meta-analysis followed the PRISMA guidelines. The random-effects model was employed to estimate the overall effect size (ES). Overall, 25 meta-analyses were included. In the standardized mean difference analysis, vitamin D significantly decreased TG (ES: -0.15; 95% CI: -0.23, -0.08; P ≤ 0.001) and TC levels (ES: -0.17; 95% CI: -0.23, -0.11; P ≤ 0.001) and increased HDL levels (ES: 0.08; 95% CI: 0.01, 0.15; P = 0.025). In the weighted mean difference analysis, vitamin D significantly decreased only TG levels (ES: -4.63 mg/dL; 95% CI: -7.70, -1.57; P = 0.003). The present study supports that vitamin D supplementation could be considered a beneficial adjuvant therapy in managing lipid profile levels, especially in individuals with vitamin D deficiency. This systematic review was registered in PROSPERO as CRD42022306334.

10 October 2023 in Preventive Medicine Reports
Verified
Journal Article
Open access
NRNima Radkhah
Nima Radkhah
ARAhmadreza Rasouli
Ahmadreza Rasouli
AMAmin Majnouni
Amin Majnouni
EEEslam Eskandari
Eslam Eskandari
KPKarim Parastouei
Karim Parastouei
Evidence suggests that adopting a healthy diet, such as the Mediterranean Diet (MD), can positively affect mental health. To further explore this, a study was conducted to determine the impact of MD instruction over 12 weeks on depression, anxiety, stress, and anthropometric indices. The study is a randomized, double-blind, controlled clinical trial with sixty participants who reported stress, anxiety, and depression conducted in Tabriz, Iran (2022–2023). They were randomly assigned to either the intervention group (n = 30), which received MD instruction, or the control group (n = 30), which received standard healthy nutrition education. Both groups were asked to follow their respective nutrition education plans for 12 weeks. After 12 weeks, depression, anxiety, and stress levels were measured using the DASS-21 questionnaire, and anthropometric indices were assessed. Initially, the unadjusted DASS-21 scores for depression, anxiety, and stress did not show significant differences between the two groups. However, after adjusting for baseline variables (model 2), all scores decreased significantly (the P-value for all scores was < 0.001). There was no significant difference in weight and BMI between the intervention and control groups. However, after adjusting the results based on baseline values (Model 2) and adherence to the program (Model 3), weight and BMI were significantly reduced in the MD group (P-values for both cases and both models were < 0.001). Overall, despite some significant findings, the results were not noticeable from a clinical perspective. The study provides some indications that following the Mediterranean diet may lead to improvements in weight and mental well-being.

24 April 2024 in Public Health Nutrition
Verified
Journal Article
Open access
PDF file
AJAbdolreza Jamilian
Abdolreza Jamilian
FGFaezeh Ghalichi
Faezeh Ghalichi
FKFatemeh Hamedi Kalajahi
Fatemeh Hamedi Kalajahi
NRNima Radkhah
Nima Radkhah
NJNeda Jourabchi
Neda Jourabchi
AOAlireza Ostadrahimi
Alireza Ostadrahimi
Objectives: Several meta-analyses have suggested the beneficial effect of vitamin D on patients infected with severe acute respiratory syndrome coronavirus-2. This umbrella meta-analysis aims to evaluate influence of vitamin D supplementation on clinical outcomes and the mortality rate of COVID-19 patients. Design: Present study was designed as an umbrella meta-analysis. The following international databases were systematically searched till March 2023: Web of Science, PubMed, Scopus, and Embase. Settings: Random-effects model was employed to perform meta-analysis. Using AMSTAR critical evaluation tools, the methodological quality of the included meta-analyses was evaluated. Participants: Adult patients suffering from COVID-19 were studied. Results: Overall, 13 meta-analyses summarising data from 4 randomised controlled trial and 9 observational studies were identified in this umbrella review. Our findings revealed that vitamin D supplementation and status significantly reduced mortality of COVID-19 [Interventional studies: (ES = 0·42; 95 % CI: 0·10, 0·75, P < 0·001; I2 = 20·4 %, P = 0·285) and observational studies (ES = 1·99; 95 % CI: 1·37, 2·62, P < 0·001; I2 = 00·0 %, P = 0·944). Also, vitamin D deficiency increased the risk of infection and disease severity among patients. Conclusion: Overall, vitamin D status is a critical factor influencing the mortality rate, disease severity, admission to intensive care unit and being detached from mechanical ventilation. It is vital to monitor the vitamin D status in all patients with critical conditions including COVID patients.

17 March 2021 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
PDF file
NRNima Radkhah
Nima Radkhah
SSSakineh Shab-Bidar
Sakineh Shab-Bidar
MZMeysam Zarezadeh
Meysam Zarezadeh
ASAbdolrasoul Safaeiyan
Abdolrasoul Safaeiyan
ABAli Barzegar
Ali Barzegar
Cardiovascular disease (CVD) is a leading cause of death around the world. According to the studies, apolipoproteins A1 and B100 play crucial role in CVD development and progression. Also, findings have indicated the positive role of vitamin D on these factors. Thus, we conducted the present meta-analysis of randomized controlled trials (RCTs) to demonstrate the impact of vitamin D supplementation on apolipoproteins A1 and B100 levels in adults. PubMed and Scopus databases and Google Scholar were searched up to 21 December 2020. Relevant articles were screened, extracted, and assessed for quality based on the Cochrane collaboration’s risk of bias tool. Data analysis conducted by random-effect model and expressed by standardized mean difference (SMD). The heterogeneity between studies was assessed by I-squared (I2) test. Subgroups and sensitivity Analyses were also conducted. Seven RCTs were identified investigating the impact of vitamin D on Apo A1 levels and six on Apo B100 levels. The findings showed the insignificant effect of vitamin D supplementation on Apo A1 (SMD=0.26 mg/dL; 95% confidence interval (CI), −0.10, 0.61; P= 0.155) and Apo B100 (standardized mean difference (SMD)=-0.06 mg/dL; 95% CI, −0.24, 0.12; P=0.530) in adults. There was a significant between-study heterogeneity in Apo A1 (I2=89.3%, P<0.001) and Apo B100 (I2=57.1%, P=0.030). However, significant increase in Apo A1 in daily dosage of vitamin D (SMD=0.56 mg/dL; 95% CI, 0.02, 1.11; P=0.044) and ≤12 weeks of supplementation duration (SMD=0.71 mg/dL; 95% CI, 0.08, 1.34; P=0.028) was observed. No significant effects of vitamin D on Apo A1 and Apo B100 levels after subgroup analysis by mean age, gender, study population, dosage and duration of study. Overall, daily vitamin D supplementation and ≤12 weeks of supplementation might have beneficial effects in increasing Apo A1 levels, however, future high-quality trials considering these a primary outcome are required.

11 August 2025 in Food Science & Nutrition
Verified
Journal Article
Open access
GVGita Vousoughi
Gita Vousoughi
HSHamid Soleimanzadeh
Hamid Soleimanzadeh
NRNima Radkhah
Nima Radkhah
MJMohammad Asghari Jafarabadi
Mohammad Asghari Jafarabadi
FBFatemeh Bahri
Fatemeh Bahri
VAVahideh Ebrahimzadeh Attari
Vahideh Ebrahimzadeh Attari
Kidney stones (nephrolithiasis) are a common and costly medical condition frequently linked with metabolic disorders. These disorders elevate the risk of serious complications and often necessitate invasive, expensive treatments, highlighting the need for alternative therapies. This study aimed to evaluate the effects of boron supplementation—in the form of boric acid and boron citrate—on kidney stone size and number in patients with nephrolithiasis. In this double‐blind, randomized, placebo‐controlled clinical trial, 60 eligible patients aged 20–65 years with nephrolithiasis were enrolled. Participants were randomly assigned to receive daily oral supplements for 8 weeks: boric acid (10 mg), boron citrate (10 mg), or placebo. The primary outcomes were kidney stone size and number; secondary outcomes included paraclinical parameters. Boron supplementation with either boric acid or boron citrate did not significantly reduce the number of kidney stones in fully adjusted models compared to the control group. The incidence rate ratios (IRR) were 1.09 (95% CI: 0.65–1.85; p ‐value = 0.740) for boric acid and 1.30 (95% CI: 0.79–2.13; p ‐value = 0.296) for boron citrate. Quade analysis also revealed no significant differences in kidney stone size among the groups. Regarding laboratory parameters, only urine phosphorus levels were significantly elevated in the boric acid group compared to placebo. No other clinically relevant effects were observed. Despite previous preliminary evidence, this study found no beneficial evidence for boron supplementation in patients with nephrolithiasis. Trial Registration: IRCT20210914052469N1 ( www.irct.behdasht.gov.ir )

1 January 2023 in Central European Journal of Sport Sciences and Medicine
Verified
Journal Article
Open access
PDF file
AAAkram Amaghani
Akram Amaghani
BGBahram Jamali Gharakhanlou
Bahram Jamali Gharakhanlou
AKAli Zarghami Khamneh
Ali Zarghami Khamneh
NRNima Radkhah
Nima Radkhah
Wydawnictwo Naukowe Uniwersytetu Szczecińskiego